Liquid Biopsy Market is estimated to be US$...
Why do you feel this listing needs to be reviewed?
Liquid Biopsy Market accounted for US$ 1.32 billion in 2020 and is estimated to be US$ 7.92 billion by 2030 and is anticipated to register a CAGR of 19.8%. Liquid biopsy is a non-invasive alternative to surgical biopsies that allows doctors to acquire tumor-related information from a simple blood sample. The epidermal growth factor receptor (EGFR) gene alterations that arise in people with non-small cell lung cancer can be detected using a liquid biopsy test.
67 views, Last viewed on Wednesday, May 8th, 2024 at 8:16am